[go: up one dir, main page]

CN1225466C - Ⅰ型钠-氢交换剂(nhe-1)抑制剂 - Google Patents

Ⅰ型钠-氢交换剂(nhe-1)抑制剂 Download PDF

Info

Publication number
CN1225466C
CN1225466C CNB018087256A CN01808725A CN1225466C CN 1225466 C CN1225466 C CN 1225466C CN B018087256 A CNB018087256 A CN B018087256A CN 01808725 A CN01808725 A CN 01808725A CN 1225466 C CN1225466 C CN 1225466C
Authority
CN
China
Prior art keywords
compound
tissue
pharmaceutically acceptable
prodrug
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018087256A
Other languages
English (en)
Chinese (zh)
Other versions
CN1426404A (zh
Inventor
W·G·陈
E·D·科克斯
A·古兹曼-佩雷兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1426404A publication Critical patent/CN1426404A/zh
Application granted granted Critical
Publication of CN1225466C publication Critical patent/CN1225466C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB018087256A 2000-04-28 2001-02-28 Ⅰ型钠-氢交换剂(nhe-1)抑制剂 Expired - Fee Related CN1225466C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20043200P 2000-04-28 2000-04-28
US60/200,432 2000-04-28

Publications (2)

Publication Number Publication Date
CN1426404A CN1426404A (zh) 2003-06-25
CN1225466C true CN1225466C (zh) 2005-11-02

Family

ID=22741697

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018087256A Expired - Fee Related CN1225466C (zh) 2000-04-28 2001-02-28 Ⅰ型钠-氢交换剂(nhe-1)抑制剂

Country Status (40)

Country Link
EP (1) EP1276737A1 (es)
JP (1) JP2003531900A (es)
KR (1) KR20020093079A (es)
CN (1) CN1225466C (es)
AP (1) AP2002002651A0 (es)
AR (1) AR028375A1 (es)
AU (1) AU2001235896A1 (es)
BG (1) BG107139A (es)
BR (1) BR0110268A (es)
CA (1) CA2407535A1 (es)
CO (1) CO5221125A1 (es)
CR (1) CR6797A (es)
CZ (1) CZ20023408A3 (es)
DZ (1) DZ3310A1 (es)
EA (1) EA004882B1 (es)
EE (1) EE200200615A (es)
GT (1) GT200100064A (es)
HN (1) HN2001000042A (es)
HR (1) HRP20020851A2 (es)
HU (1) HUP0300651A2 (es)
IL (1) IL152075A0 (es)
IS (2) IS6567A (es)
MA (1) MA26897A1 (es)
MX (1) MXPA02010600A (es)
MY (1) MY133842A (es)
NO (1) NO20025132L (es)
NZ (1) NZ521348A (es)
OA (1) OA12256A (es)
PA (1) PA8513301A1 (es)
PE (1) PE20011270A1 (es)
PL (1) PL357765A1 (es)
SK (1) SK14872002A3 (es)
SV (1) SV2002000418A (es)
TN (1) TNSN01065A1 (es)
TR (1) TR200202439T2 (es)
UA (1) UA73348C2 (es)
UY (1) UY26680A1 (es)
WO (1) WO2001083470A1 (es)
YU (1) YU79602A (es)
ZA (1) ZA200208605B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL156220A0 (en) * 2001-01-31 2003-12-23 Pfizer Prod Inc Ethanolates of sodium-hydrogen exchanger type-1 inhibitor
MXPA04004685A (es) * 2001-12-19 2004-08-12 Pfizer Prod Inc Procedimientos para preparar inhibidores de tipo-1 de intercambiador sodio-hidrogeno.
EP1499317A1 (en) * 2002-05-02 2005-01-26 Pfizer Products Inc. Treatment of diabetes and diabetic complications with nhe-1 inhibitors
FR2840302B1 (fr) * 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
ES2220185B1 (es) * 2002-07-16 2006-04-01 Consejo Sup. De Investig. Cientificas Nuevo peptido inhibidor del intercambiador na+/h+ (pinhe), y sus aplicaciones.
JP2006517976A (ja) * 2003-02-14 2006-08-03 スミスクライン・ビーチャム・コーポレイション 新規化合物
RU2518741C1 (ru) * 2013-03-22 2014-06-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" СРЕДСТВО, ИНГИБИРУЮЩЕЕ Na+/H+-ОБМЕН, И ГАЛОГЕНИДЫ 1-ДИАЛКИЛАМИНОЭТИЛ-3-[ЗАМЕЩЕННЫЙ(ДИЗАМЕЩЕННЫЙ) ФЕНАЦИЛ]-2-АМИНОБЕНЗИМИДАЗОЛИЯ

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030078886A (ko) * 1998-02-27 2003-10-08 화이자 프로덕츠 인크. 허혈 치료용 n-[(치환된 5원 트리아자 이불포화고리)카르보닐] 구아니딘 유도체

Also Published As

Publication number Publication date
NO20025132D0 (no) 2002-10-25
MXPA02010600A (es) 2003-03-10
PE20011270A1 (es) 2001-12-12
CO5221125A1 (es) 2002-11-28
IS6567A (is) 2002-09-24
IL152075A0 (en) 2003-05-29
EA004882B1 (ru) 2004-08-26
PL357765A1 (en) 2004-07-26
GT200100064A (es) 2002-03-22
CA2407535A1 (en) 2001-11-08
WO2001083470A1 (en) 2001-11-08
CR6797A (es) 2004-05-17
CN1426404A (zh) 2003-06-25
JP2003531900A (ja) 2003-10-28
TNSN01065A1 (fr) 2005-11-10
MY133842A (en) 2007-11-30
NO20025132L (no) 2002-12-12
AR028375A1 (es) 2003-05-07
CZ20023408A3 (cs) 2004-01-14
UY26680A1 (es) 2001-12-28
HN2001000042A (es) 2001-07-09
ZA200208605B (en) 2003-10-24
EA200201023A1 (ru) 2003-02-27
UA73348C2 (en) 2005-07-15
AP2002002651A0 (en) 2002-12-31
OA12256A (en) 2003-11-06
AU2001235896A1 (en) 2001-11-12
MA26897A1 (fr) 2004-12-20
YU79602A (en) 2006-05-25
HUP0300651A2 (hu) 2003-07-28
IS6588A (is) 2002-10-21
SV2002000418A (es) 2002-07-03
EE200200615A (et) 2004-04-15
NZ521348A (en) 2004-09-24
EP1276737A1 (en) 2003-01-22
TR200202439T2 (tr) 2003-02-21
KR20020093079A (ko) 2002-12-12
SK14872002A3 (sk) 2004-03-02
DZ3310A1 (fr) 2001-11-07
BR0110268A (pt) 2003-12-30
HRP20020851A2 (en) 2005-02-28
PA8513301A1 (es) 2003-09-05
BG107139A (bg) 2003-07-31

Similar Documents

Publication Publication Date Title
JP4184378B2 (ja) ジペプチジルペプチダーゼivを阻害する化合物
JP2003500403A (ja) p38キナーゼのインヒビターとしてのインドール型誘導体
KR20150028971A (ko) 항바이러스성 화합물의 고체 형태
CN1450991A (zh) 脱乙酰酶抑制剂
CN1726191A (zh) 用作纤溶酶原激活物抑制剂-1(pai-1)的抑制剂的取代的吲哚氧代-乙酰氨基乙酸衍生物
EA021025B1 (ru) Соединения, эффективные в качестве ингибиторов ксантиноксидазы, способ их получения и содержащая их фармацевтическая композиция
EP2838531B1 (en) Indolin-2-one derivatives as protein kinase inhibitors
TW200922934A (en) Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use
TW200927729A (en) 4-heteroaryl-substituted phenoxyphenylacetic acid derivatives
CN1225466C (zh) Ⅰ型钠-氢交换剂(nhe-1)抑制剂
KR100464526B1 (ko) 나트륨-수소 교환체 타입 1 억제제 결정
CN1058397A (zh) 1-二苯甲基哌嗪的新颖衍生物,其制备方法及其医药用途
HK1056723A (en) Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)
JPH0696555B2 (ja) カルボスチリル誘導体
US6852733B2 (en) Sodium-hydrogen exchanger type 1 inhibitor
TWI221152B (en) Method for preparing sodium-hydrogen exchanger type 1 inhibitor
US20100222365A1 (en) Substituted triazole deriviatives as oxytocin antagonists
CN1234032A (zh) 新的2,4-二氧代吡咯烷和2,4-二氧代四氢呋喃衍生物以及含有它们作为活性成分的药物
WO2024059333A1 (en) Compounds for treating infections with parasitic protozoa
JP2008308434A (ja) 1,3−ベンゾチアジノン誘導体およびその用途
CN101065378A (zh) 作为因子Xa抑制剂的吡唑并[3,4-c]吡啶的晶型

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1056723

Country of ref document: HK